Liver X Receptor

亜型選択性的な製品

Liver X Receptor製品

• All (15)
• Liver X Receptor拮抗剤(1)
• Liver X Receptor作動薬(7)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Regen Ther, 2024, 25:229-237 Cell Death Dis, 2023, 14(2):85 Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E1142	GSK2033	GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Regen Ther, 2024, 25:229-237 Cell Death Dis, 2023, 14(2):85 Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E1142	GSK2033	GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Regen Ther, 2024, 25:229-237 Cell Death Dis, 2023, 14(2):85 Mol Oral Microbiol, 2023, 10.1111/omi.12447
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.